Glioblastoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 76 expanded access programs, clinical trials, and compassionate use pathways listed for Glioblastoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with glioblastoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 26 programs are currently active or recruiting, with the remaining 50 in other lifecycle stages. Sponsors actively running programs in this area include National Cancer Institute (NCI), Mayo Clinic, Northwell Health, Case Comprehensive Cancer Center, GT Medical Technologies, Inc., and others.
By recruiting status
Snapshot of where every Glioblastoma program currently sits in its lifecycle.
- Active / Recruiting26
- Inactive50
Top sponsors
Organisations running the most Glioblastoma programs in the directory.
- National Cancer Institute (NCI)7 programs
- Mayo Clinic4 programs
- Northwell Health4 programs
- Case Comprehensive Cancer Center2 programs
- GT Medical Technologies, Inc.2 programs
- M.D. Anderson Cancer Center2 programs
- Memorial Sloan Kettering Cancer Center2 programs
- NRG Oncology2 programs
- The University of Texas Health Science Center at San Antonio2 programs
- Weill Medical College of Cornell University2 programs
Glioblastoma programs (76)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on ST101 for Patients with Advanced Solid Tumors — Sapience Therapeutics
- Phase 2 Study of Sitagliptin for Patients with Advanced Brain Tumors (Grade 4 Gliomas) — Case Comprehensive Cancer Center
- Phase 2b Study of Combination Immunotherapy for Newly Diagnosed Glioblastoma Patients — Imvax
- Phase I/II Study of IVONESCIMAB for Recurrent Glioblastoma — M.D. Anderson Cancer Center
- Study on Abemaciclib for Treating Recurrent Glioblastoma — Dana-Farber Cancer Institute
- Study on L19TNF and Lomustine for Patients with Glioblastoma at Progression or Recurrence — Philogen S.p.A.
- Study on Using Ultrasound and a New Drug with Temozolomide for Treating Newly Diagnosed Glioblastoma — Alpheus Medical, Inc.
- Study on Azeliragon and Radiation Therapy for a Type of Brain Cancer Called Unmethylated Glioblastoma — Cantex Pharmaceuticals
- Study on Starting Radiation Immediately with GammaTile During GBM Surgery Compared to Standard Treatment — GT Medical Technologies, Inc.
- Study on DC Migration to Evaluate TReg Depletion in Glioblastoma Patients With and Without Varlilumab — Annick Desjardins, MD
- Study on High-Dose Radiation Therapy with Temozolomide for Newly Diagnosed Glioblastoma — NRG Oncology
- Phase 3 Study of Optune with Temozolomide and Pembrolizumab for Newly Diagnosed Glioblastoma — NovoCure GmbH
- Expanded Access Program for Patients with Glioblastoma (GBM) — Rznomics, Inc.
- Study on Intraoperative Radiotherapy for Newly Diagnosed Glioblastoma Multiforme — Universitätsmedizin Mannheim
- Study on Niraparib and Tumor-Treating Fields for Recurrent Glioblastoma — Abramson Cancer Center at Penn Medicine
- Study Comparing Nivolumab with Standard and Low Dose Bevacizumab for Glioblastoma — David Peereboom
- Study on Nivolumab with Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma — Memorial Sloan Kettering Cancer Center
- NuvOx Expanded Access Program for NanO₂ — NuvOx LLC
- Study on Olaparib for Treating Advanced Glioma, Cholangiocarcinoma, or Solid Tumors with IDH1 or IDH2 Mutations — National Cancer Institute (NCI)
- Study on Pembrolizumab and Standard Therapy for Treating Glioblastoma — Mayo Clinic
- Study on Ruxolitinib with Radiation and Temozolomide for Newly Diagnosed Glioblastoma — Baptist Health South Florida
- Study on the Safety and Effectiveness of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma — Washington University School of Medicine
- Short Course Chemo-Radiation Therapy for Newly Diagnosed Glioblastoma Patients — John Flickinger
- Study on Temozolomide With or Without Veliparib for Newly Diagnosed Glioblastoma Multiforme — National Cancer Institute (NCI)
- Home-Based Cancer Treatment Program for Patients in the Florida Panhandle and Nearby Areas — Mayo Clinic
- Study on Veliparib, Radiation Therapy, and Temozolomide for Treating Newly Diagnosed Malignant Glioma Without Specific Mutations — National Cancer Institute (NCI)
- Study on a Hemp-Derived High CBD Product for Anxiety in Glioblastoma Patients — Mclean Hospital
- Study on Drug Resistant Immunotherapy with Gene Modified T Cells and Chemotherapy for Glioblastoma — In8bio Inc.
- Pilot Study on Ketogenic Diet and Metformin for Glioblastoma: Feasibility and Metabolic Imaging — Weill Medical College of Cornell University
- Study Comparing Niraparib and Temozolomide for Newly Diagnosed Glioblastoma Patients — Ivy Brain Tumor Center
- Study on BPM31510 with Vitamin K1 for Patients with Newly Diagnosed Glioblastoma — BPGbio
- Study of Selinexor and Radiation Therapy for Newly Diagnosed Brain Tumors in Children and Young Adults — National Cancer Institute (NCI)
- Study on Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70 — University of Louisville
- Trial to Test Different Treatments for Newly Diagnosed and Recurrent Glioblastoma — Global Coalition for Adaptive Research
- Study on Using Pulsed Reduced Dose Radiotherapy for Initial Treatment of Glioblastoma — Medical College of Wisconsin
- Study on Immune Response to Treatment with Immune Checkpoint Inhibitors in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma — National Cancer Institute (NCI)
- Study on Chemotherapy and Radiation Therapy for Treating IDH Wildtype Gliomas or Molecular Glioblastomas — M.D. Anderson Cancer Center
- Comparing Telehealth and In-Person Check-Ups for Glioma Patients on Oral Chemotherapy — Mayo Clinic
- Study on Dabrafenib and Trametinib After Radiation Therapy for Newly Diagnosed High-Grade Glioma — National Cancer Institute (NCI)
- Study on ERC1671, GM-CSF, and Cyclophosphamide for Treating Glioblastoma Multiforme — Epitopoietic Research Corporation
- Expanded Access to Gallium Maltolate (GaM) for Patients with Relapsed or Hard-to-Treat Glioblastoma — Imaging Biometrics, LLC
- Access to AVM0703 for Patients with Solid Tumors and Blood Cancers — AVM Biotechnology Inc
- Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies — xCures
- Study on GammaTile and Stupp Protocol for Newly Diagnosed Glioblastoma (GBM) — GT Medical Technologies, Inc.
- Study on Gene Therapy, Radiation, and Chemotherapy for Newly Diagnosed Brain Tumors (GBM and AA) — The Methodist Hospital Research Institute
- Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) — Patrick Wen, MD
- Study on Imipramine Hydrochloride and Lomustine for Recurrent Glioblastoma — The University of Texas Health Science Center at San Antonio
- Study on Methimazole for Patients with Progressive Glioblastoma — Case Comprehensive Cancer Center
- Study on High Dose Adaptive Radiotherapy with Temozolomide for Newly Diagnosed Glioblastoma — University of Michigan Rogel Cancer Center
- Study on N-803 and PD-L1 t-haNK Combined with Bevacizumab for Recurrent or Worsening Glioblastoma — ImmunityBio, Inc.
- Study on Chemoradiation Before Surgery for Treatable Glioblastoma — Geisinger Clinic
- Study on Nivolumab for Patients with IDH-Mutant Gliomas with and without High Mutation Levels — National Cancer Institute (NCI)
- Study on Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed Glioblastoma Multiforme (GBM) — Northwell Health
- Study on Paxalisib with a High Fat, Low Carb Diet and Metformin for Glioblastoma — Weill Medical College of Cornell University
- Pediatric Long-Term Follow-up and Rollover Study — Novartis Pharmaceuticals
- Pediatric Study of Indoximod with Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG — Theodore S. Johnson
- Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma — Nerviano Medical Sciences
- Study on Using Advanced MRI Techniques to Improve Surgery Outcomes in Glioblastoma Patients — Jonsson Comprehensive Cancer Center
- Study on Lurbinectedin and Irinotecan for Patients with Certain Advanced Cancers — PharmaMar
- Study on Radiation, Temozolomide, and Immunotherapy with Daratumumab to Improve Treatment in Glioblastoma — West Virginia University
- Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM — Northwell Health
- Sacituzumab Govitecan in Recurrent Glioblastoma — The University of Texas Health Science Center at San Antonio
- Study on the Safety and Effectiveness of Bevacizumab with NaviFUS System for Treating Recurrent Glioblastoma Multiforme — NaviFUS Corporation
- Study on Short Course Radiotherapy for Treating Glioblastoma: SAGA Study — Mayo Clinic
- Study on SonoCloud-9 with Carboplatin vs. Standard Chemotherapies for Recurrent Glioblastoma — CarThera
- Study on Liposomal Curcumin with Radiation and Chemotherapy for Newly Diagnosed High-Grade Brain Tumors — SignPath Pharma, Inc.
- Study on NGM707 Alone and with Pembrolizumab for Advanced or Metastatic Solid Tumors — NGM Biopharmaceuticals, Inc
- Study on Ribociclib and Everolimus for Treating High-Grade Glioma and DIPG in Children and Young Adults — Nationwide Children's Hospital
- Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA — Northwell Health
- Study on Repeated Intra-arterial Infusion of Cetuximab for Treating Newly Diagnosed Glioblastoma — Northwell Health
- Study on Surgery with Pembrolizumab, Olaparib, and Temozolomide for Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
- Evaluating the Addition of Lomustine to Standard Treatment for Newly Diagnosed MGMT Methylated Glioblastoma — NRG Oncology
- Study on Tofacitinib for Patients with Recurrent Glioblastoma — University of Texas Southwestern Medical Center
- Study on Trastuzumab Deruxtecan (T-DXd) for Treating Brain Cancer — Memorial Sloan Kettering Cancer Center
- Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma — Northwestern University
- Study on Verteporfin for Treating Recurrent High Grade EGFR-Mutated Glioblastoma — Emory University
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Glioblastoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.